Monday, April 27, 2015
The T-cell "World"
Chairmen: F. Pane, S.A. Pileri
2.45 p.m.
News from WHO
E.S. Jaffe
3.05 p.m.
Epidemiologic view on ALCL of the breast
H.M. Prince
3.25 p.m.
Prognostic models in PTCL
J.M. Vose
3.45 p.m.
Prognostic models in CTCL
Y.H. Kim
4.05 p.m.
The role of PET and T-cell specific response criteria
B.D. Cheson
Conventional and ongoing therapies
Chairmen: R. Advani, P.L. Zinzani
04.25 p.m.
PTCL-nos
K.J. Savage
04.45 p.m.
«The rest» of PTCL
S.M. Horwitz
05.05 p.m.
CTCL
R. Willemze
05.25 p.m.
ATLL
K. Tobinai
05.45 p.m.
ACT-1/ACT-2
F.A. D'Amore
06.10 p.m.
CHOP vs. GEM-P
C. Dearden
06.20 p.m.
CHOP vs. A+CHP
R. Advani
06.30 p.m.
CHOP vs Ro-CHOP
B. Coiffier
Tuesday April 28, 2015
PTCL: morphology and pathobiology
Chairmen: B. Falini, B. Nathwani
08.30 a.m.
Histology
E. Sabattini
08.50 a.m.
Lennert's lymphoma
M.L. Hansmann
09.10 a.m.
Gene expression profiling
W.C. Chan
09.30 a.m.
AITL
P. Gaulard
09.50 a.m.
ALCL
S.A. Pileri
PTCL and CTCL CD30+
Chairmen: M. Federico, M. Paulli
10.45 a.m.
CD30+ expression: real or virtual?
S.A. Pileri
11.05 a.m.
ALCL
B. Pro
11.25 a.m.
PTCL-NOS/AILT
M. Fanale
11.45 a.m.
CTCL
M. Duvic
NK/T-cell lymphoma: the role of asparaginase
Chairmen: W.S. Kim, K. Tobinai
12.05 p.m.
Japanese experience
M. Yamaguchi
12.20 p.m.
Hong Kong experience
Y.L. Kwong
12.35 p.m.
French experience
A. Jaccard
12.50 p.m.
Chinese experience
H.Q. Huang
01.05 p.m.
NCCN guidelines
R. Advani
PTCL: the "combo-step" of the new drugs
Chairmen: B.D. Cheson, P.L. Zinzani
02.45 p.m.
Romidepsin and...
M. Fanale
03.00 p.m.
Belinostat plus...
F. Foss
03.15 p.m.
Everolimus with...
W.S. Kim
03.30 p.m.
Lenalidomide and...
S.M. Horwitz
PTCL: the new single agents
Chairmen: F. Foss, S.M. Horwitz
04.15 p.m.
PD-1, PDL-1
S.M. Ansell
04.30 p.m.
Copanlisib
P.L. Zinzani
04.45 p.m.
What from the basket of BTK and PI3K inhibitors?
S.M. Horwitz
05.00 p.m.
Carlfizomib
J.M. Vose
05.15 p.m.
Bendamustine
G. Damaj
05.30 p.m.
Crizotinib
C. Gambacorti-Passerini
Wednesday April 29, 2015
CTCL: morphology and pathobiology
Chairmen: E. Berti, S.A. Pileri
08.30 a.m.
Histology
M. Santucci
09.00 a.m.
The spectrum of CD8+ CTCL
E. Berti
CTCL and New Drugs: Emerging combination strategies
Chairmen: N. Pimpinelli, P. Quaglino
09.30 a.m.
Pralatrexate with...
M. Duvic
09.45 a.m.
Pegylated liposomal doxorubicin
R. Dummer
10.00 a.m.
Bexarotene-containing regimens
N. Pimpinelli
10.15 a.m.
HS IPH4102 anti-KIR3DL2 mAb in CTCL
H. Sicard
Mogamulizumab inside the T-cell family
Chairman: K. Tobinai
10.30 a.m.
ATLL
K. Tsukasaki
10.45 a.m.
PTCL
K. Tobinai
11.00 a.m.
CTCL
M. Duvic
Important Pre-clinical Model with T-cell lymphoma
Chairman: G. Gaidano
11.55 a.m.
Animal models
G. Inghirami
Allotransplant setting
Chairman: F. Onida
12.45 p.m.
European perspective
M. Bagot
01.00 p.m.
American perspective
M. Duvic
